Search results
Showing 16 to 30 of 30 results for daratumumab
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
In development [GID-TA11201] Expected publication date: 19 March 2025
In development [GID-TA10912] Expected publication date: 16 July 2025
Awaiting development [GID-TA11162] Expected publication date: TBC
Awaiting development [GID-TA11254] Expected publication date: TBC
imatinib (review) TA510 Multiple myeloma (relapsed, refractory) - daratumumab (after proteasome inhibitor and immunomodulatory agent)...
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)
This guidance has been updated and replaced by NICE technology appraisal guidance 783.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.
In development [GID-TA10726] Expected publication date: TBC
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.